Lamivudine

Generic Name: Lamivudine

Brand Names: Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₁N_₃O_₃S

CAS Number: 134678-17-4

Unique Ingredient Identifier: 2T8Q726O95

Background: A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication: For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions: Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Islatravir (ISL)
Drug: Lamivudine (3TC)

First Posted Date: 2025-02-06

Last Posted Date: 2025-02-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 20

Registration Number: NCT06811246

Locations: 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

Phase 2

Recruiting

Conditions: Mild Cognitive Impairment

Interventions: Drug: Lamivudine 300 MG

First Posted Date: 2024-07-25

Last Posted Date: 2024-10-31

Lead Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Target Recruit Count: 25

Registration Number: NCT06519357

Locations: 🇪🇸
Germans Trias I Pujol Hospital, Badalona, Barcelona, Spain

Antiviral Therapy in Infants With HBV Infection

Phase 4

Not yet recruiting

Conditions: HBV

Interventions: Drug: Lamivudine
Drug: Interferon

First Posted Date: 2024-07-16

Last Posted Date: 2024-07-23

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 60

Registration Number: NCT06503796

Locations: 🇨🇳
the Fifth Medical Center of PLA, Beijing, China

Lamivudine for Solid Tumors

Phase 1

Recruiting

Conditions: Relapsed/Refractory Solid Tumors

Interventions: Drug: Lamivudine
Drug: PD-L1 Blocker

First Posted Date: 2024-07-10

Last Posted Date: 2024-10-24

Lead Sponsor: Thomas Marron

Target Recruit Count: 24

Registration Number: NCT06494579

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

STARLITE for Unresectable High-Grade Gliomas

Phase 1

Recruiting

Conditions: High Grade Glioma

Interventions: Procedure: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)
Drug: Abacavir
Drug: Lamivudine
Drug: Ritonavir
Drug: Temozolomide
Radiation: Focal Radiotherapy

First Posted Date: 2024-05-24

Last Posted Date: 2025-04-17

Lead Sponsor: University of Miami

Target Recruit Count: 24

Registration Number: NCT06428045

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Early Phase 1

Recruiting

Conditions: Rhegmatogenous Retinal Detachment
Retinal Detachment

Interventions: Drug: Lamivudine 300 MG
Drug: Placebo

First Posted Date: 2023-09-28

Last Posted Date: 2024-08-29

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 20

Registration Number: NCT06056596

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

Phase 3

Recruiting

Conditions: HIV
HIV Infections

Interventions: Drug: Dolutegravir
Drug: Bictegravir
Drug: Lamivudine
Drug: Emtricitabine
Drug: Tenofovir alafenamide

First Posted Date: 2023-08-07

Last Posted Date: 2024-08-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 412

Registration Number: NCT05979311

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients

Not yet recruiting

Conditions: HIV-1-infection

First Posted Date: 2022-04-18

Last Posted Date: 2022-04-18

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 200

Registration Number: NCT05332470

Triumeq in Amyotrophic Lateral Sclerosis

Phase 3

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Dolutegravir, Abacavir and Lamivudine
Drug: Placebo

First Posted Date: 2022-01-18

Last Posted Date: 2025-04-18

Lead Sponsor: Macquarie University, Australia

Target Recruit Count: 390

Registration Number: NCT05193994

Locations: 🇦🇺
Neuroscience Research Australia (NeuRA), Randwick, New South Wales, Australia
🇳🇿
Dunedin Hospital, Dunedin, New Zealand
🇦🇺
MQ Health Neurology, North Ryde, New South Wales, Australia

and more 25 locations

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

Phase 2

Terminated

Conditions: HIV Infections

Interventions: Drug: GSK3640254
Drug: Lamivudine capsules
Drug: Dolutegravir
Drug: Lamivudine tablets

First Posted Date: 2021-05-25

Last Posted Date: 2023-12-14

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 85

Registration Number: NCT04900038

Locations: 🇪🇸
GSK Investigational Site, Vigo, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy